| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Nuwellis, Inc. (NASDAQ:NUWE) shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting.
The Details:
Quelimmune is a novel therapy designed to treat pediatric patients suffering from acute kidney injury (AKI) with sepsis or a septic condition and requiring kidney replacement therapy (KRT) manufactured for SeaStar Medical Holding Corp (NASDAQ:ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis.
Read Next: What’s Going On With Lululemon Stock?
“We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis’ mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions,” said Nestor Jaramillo, CEO of Nuwellis.
Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and a $17 price target Monday. According to data from Benzinga Pro, Nuwellis shares are trading below the stock’s 50-day moving average of $6.30 and near its 52-week low of $2.19.
By now you're likely curious about how to participate in the market for Nuwellis – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
NUWE Price Action: According to Benzinga Pro, Nuwellis shares are up 20.8% at $2.90 at the time of publication Monday.
Read Also:
Image: Unsplash
